RADIOGARDASE (PRUSSIAN BLUE)
LOE Approachingprussian blue insoluble capsules
NDAORALCAPSULEPriority Review
Approved
Oct 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
RADIOGARDASE (PRUSSIAN BLUE) (prussian blue insoluble capsules) is ion exchange activity [moa]. Approved for suspected internal contamination with radioactive cesium and/or radioactive, non-radioactive thallium to increase their rates of elimination. First approved in 2003.
Drug data last refreshed 20h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RADIOGARDASE (Prussian blue insoluble capsules) is an oral decorporation agent that uses ion exchange activity to bind radioactive cesium and non-radioactive thallium in the gastrointestinal tract, enhancing their elimination from the body. It is indicated for patients with suspected internal contamination from radiological or nuclear incidents. This niche specialty product addresses a critical gap in emergency preparedness and radiation toxicology.
LOE Approaching
As a specialty product in LOE-approaching stage with moderate competitive pressure (30), the brand team is likely focused on market defense and niche retention rather than growth expansion.
Mechanism of Action
Ion Exchange Activity
Pharmacologic Class:
Decorporation Agent
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.